A carregar...
A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options. Vascular endothelial growth factor (VEGF) receptor inhibition is one potential mechanism by which AML and MDS could be treated. The receptor tyrosine kinase inhib...
Na minha lista:
| Publicado no: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4451441/ https://ncbi.nlm.nih.gov/pubmed/25329007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.977886 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|